BRIEF—EFPIA tells member states to 'get EMA relocation right'

A trade group representing pharma in Europe has reiterated its stance in relation to the post-Brexit relocation of the European Medicines Agency (EMA).

Next week, European Union member states will vote on the new location of the agency, and The Pharma Letter has looked at some of the  leading contenders and given its prediction on which the winning city might be.

The European Federation of Pharmaceutical Industries and Associations (EFPIA), which brings together 33 national associations and 41 pharma companies operating in Europe, has  previously stressed that disruption to the EMA’s activities and decisions that might impact patients should be kept to a minimum in the event of a move.

Without stating a preference, the director general of EFPIA, Nathalie Moll, voiced her view again this week, saying: “As we are now just a week from the vote, we are calling upon member states to base their decision on supporting the continuity of the EMA’s critical functions, its ability to retain staff and access expert networks.

“With the numerous technical aspects that need to be managed to ensure continuity of care for patients in relation to Brexit, Europe must get the EMA’s relocation right.”